^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Sarcoma
    Drug:Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Uterine sarcoma: Systemic therapy for uterine sarcoma…Other recommended regimens…Eribulin (category 2B)